Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Amato

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Biomedicines|November 27, 2024
Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. <i>Biomedicines</i> 2022, <i>10</i>, 985Teresa Musumeci, Giulia Di Benedetto, Claudia Carbone, et al.
European Journal of Endocrinology|February 25, 2006
Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolismGherardo Mazziotti, Giovanni Amato, Francesca Sorvillo, et al.
The Lancet. Oncology|September 17, 2013
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
The Lancet. Respiratory Medicine|May 19, 2018
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 studyLuana Calabrò, Aldo Morra, Diana Giannarelli, et al.
The Lancet. Respiratory Medicine|March 31, 2015
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 studyLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
Cancers|February 9, 2020
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with SurvivalCarla Chiarucci, Sara Cannito, Maria Grazia Daffinà, et al.
Oncoimmunology|August 17, 2017
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patientsCristina Maccalli, Diana Giannarelli, Carla Chiarucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2024
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531]Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Biomedicines|November 27, 2024
Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. <i>Biomedicines</i> 2022, <i>10</i>, 985Teresa Musumeci, Giulia Di Benedetto, Claudia Carbone, et al.
European Journal of Endocrinology|February 25, 2006
Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolismGherardo Mazziotti, Giovanni Amato, Francesca Sorvillo, et al.
The Lancet. Oncology|September 17, 2013
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
The Lancet. Respiratory Medicine|May 19, 2018
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 studyLuana Calabrò, Aldo Morra, Diana Giannarelli, et al.
The Lancet. Respiratory Medicine|March 31, 2015
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 studyLuana Calabrò, Aldo Morra, Ester Fonsatti, et al.
Cancers|February 9, 2020
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with SurvivalCarla Chiarucci, Sara Cannito, Maria Grazia Daffinà, et al.
Oncoimmunology|August 17, 2017
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patientsCristina Maccalli, Diana Giannarelli, Carla Chiarucci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2024
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531]Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
Pageof 4